Literature DB >> 18844202

The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.

Bert Willis1, Lisa M Eubanks, Tobin J Dickerson, Kim D Janda.   

Abstract

In the classic novella "The Strange Case of Dr. Jekyll and Mr. Hyde", Robert Louis Stevenson paints a stark picture of the duality of good and evil within a single man. Botulinum neurotoxin (BoNT), the most potent known toxin, possesses an analogous dichotomous nature: It shows a pronounced morbidity and mortality, but it is used with great effect in much lower doses in a wide range of clinical scenarios. Recently, tremendous strides have been made in the basic understanding of the structure and function of BoNT, which have translated into widespread efforts towards the discovery of biomacromolecules and small molecules that specifically modulate BoNT activity. Particular emphasis has been placed on the identification of inhibitors that can counteract BoNT exposure in the event of a bioterrorist attack. This Review summarizes the current advances in the development of therapeutics, including vaccines, peptides, and small-molecule inhibitors, for the prevention and treatment of botulism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844202     DOI: 10.1002/anie.200705531

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  43 in total

1.  High-level expression, purification, crystallization and preliminary X-ray crystallographic studies of the receptor-binding domain of botulinum neurotoxin serotype D.

Authors:  Yanfeng Zhang; Xiaoli Gao; Ling Qin; Garry W Buchko; Howard Robinson; Susan M Varnum
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-11-25

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease.

Authors:  Peter Šilhár; Sami Alakurtti; Kateřina Čapková; Feng Xiaochuan; Charles B Shoemaker; Jari Yli-Kauhaluoma; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

4.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel.

Authors:  Audrey Fischer; Yuya Nakai; Lisa M Eubanks; Colin M Clancy; William H Tepp; Sabine Pellett; Tobin J Dickerson; Eric A Johnson; Kim D Janda; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

5.  Targeting botulinum A cellular toxicity: a prodrug approach.

Authors:  Peter Silhár; Lisa M Eubanks; Hajime Seki; Sabine Pellett; Sacha Javor; William H Tepp; Eric A Johnson; Kim D Janda
Journal:  J Med Chem       Date:  2013-10-15       Impact factor: 7.446

6.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

7.  Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.

Authors:  T L Harris; C J Wenthur; A Diego-Taboada; G Mackenzie; T S Corbitt; K D Janda
Journal:  Chem Commun (Camb)       Date:  2016-03-18       Impact factor: 6.222

8.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Authors:  Igor Opsenica; James C Burnett; Rick Gussio; Dejan Opsenica; Nina Todorović; Charlotte A Lanteri; Richard J Sciotti; Montip Gettayacamin; Nicoletta Basilico; Donatella Taramelli; Jonathan E Nuss; Laura Wanner; Rekha G Panchal; Bogdan A Solaja; Sina Bavari
Journal:  J Med Chem       Date:  2011-01-25       Impact factor: 7.446

9.  Benzoquinones as inhibitors of botulinum neurotoxin serotype A.

Authors:  Paul T Bremer; Mark S Hixon; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2014-06-16       Impact factor: 3.641

10.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.